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Conclusion: A novel approach for liver SBRT at a linear 
accelerator was developed. The basis of the treatment is a 
fast VMAT plan, supplemented with a few (1-4) computer-
optimized non-coplanar IMRT beams. In terms of achievable 
tumor BED within the clinical OAR constraints, this approach 
is equivalent to time-consuming, fully non-coplanar 
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Purpose or Objective: The physical and biological 
advantages of carbon ion beams over conventional x-rays 
have not been fully exploited in particle therapy and may 
result in higher levels of local tumor control and 
improvements in normal tissue sparing. Treatment planning 
must account for physical properties of the beam as well as 
differences in the relative biological effectiveness (RBE) of 
ions compared to photons. In this work, we present a fast 
RBE calculation approach, based on the decoupling of 
physical properties and the (α/β)x. The (α/β)x ratio is 
commonly used to describe the radiosensitivity of irradiated 
cells or organs. The decoupling is accomplished within the 
framework of the repair-misrepair-fixation (RMF) model. 
 
Material and Methods: Carbon ion treatment planning was 
implemented by optimizing the RBE-weighted dose (RWD) 
distribution. Biological modeling was performed with the RMF 
and Monte Carlo Damage Simulation (MCDS) models. The RBE 
predictions are implemented efficiently by a decoupling 
approach which allows fast arbitrary changes in (α/β)x by 
introducing two decoupling variables c1 and c2. Dose-
weighted radiosensitivity parameters of the ion field are 
calculated as (Fig 1). This decoupling can be used during and 
after the optimization.  
 Carbon ion treatment plans were optimized for several 
patient cases. Predicted trends in RBE are compared to 
published cell survival data. A comparison of the RMF model 
predictions with the clinically used Local Effect Model (LEM1 




Figure 1: Axial CT slice of a treatment plan using the RMF 
model. The astrocytoma plan with two carbon ion fields was 
optimized on 3 Gy(RBE) using a spatially constant (α/β)x = 2 
Gy (αx = 0.1 Gy^-1, βx = 0.05 Gy^-2). The PTV is shown in 
red, along with 3 organs at risk: left optic nerve (green), left 
eye (orange) and left lens (brown). The panels show A) RWD, 
B) RBE, C) physical dose d and the beam geometry in D. The 
two decoupling variables c1 and c2 are shown in panels E and 
F, along with αD and βD in panels G and H. 
 
Results: The presented implementation of the RMF model is 
very fast, allowing online changes of the (α/β)x including a 
voxel-wise recalculation of the RBE. For example, a change 
of the (α/β)x including a complete biological modeling and a 
recalculation of RBE and RWD for 290000 voxels took 4 ms on 
a 4 CPU, 3.2 GHz workstation. Changing the (α/β)x of a single 
structure, e.g. a planning target volume (PTV) of 270 cm^3 
(35000 voxels), takes 1 ms in the same computational 
environment. The RMF model showed reasonable agreement 
with published data and similar trends as the LEM4. 
 
Conclusion: The RMF model is suitable for radiobiological 
modeling in carbon ion therapy and was successfully 
validated against published cell data. The derived decoupling 
within the RMF model allows extremely fast changes in 
(α/β)x, facilitating online adaption by the user. This provides 
new options for radiation oncologists, facilitating online 
variations of the RBE during treatment plan evaluation. 
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Purpose or Objective: In treatment planning for proton 
therapy, robust optimizers typically limit their scope to 
systematic setup and proton range errors. Treatment 
execution errors (patient and organ motion or breathing) are 
seldom included. In analytical dose calculation methods as 
pencil beam algorithms, the only way to simulate motion 
errors is to sample random shifts from a probability 
distribution, which increases the computation time for each 
simulated shift. However, the stochastic nature of Monte 
Carlo methods allows random errors to be simulated in a 
single dose calculation. 
 
Material and Methods: An in-house treatment planning 
system, based on worst-case scenario optimization, was used 
to create the plans. The optimizer is coupled with a super-
fast Monte Carlo (MC) dose calculation engine that enables 
computing beamlets for optimization, as well as final dose 
distributions (less than one minute for final dose). Two 
strategies are presented to account for random errors: 1) Full 
robust optimization with beamlets that already include the 
effect of random errors and 2) Mixed robust optimization, 
where the nominal beamlets are involved but a correction 
term C modifies the prescription. Starting from C=0, the 
method alternates optimization of the spot weights with the 
nominal beamlets and updates of C, with C = Drandom – 
Dnominal and where Drandom results from a regular MC 
computation (without pre-computed beamlets) that simulates 
random errors. Updates of C can be triggered as often as 
necessary by running the MC engine with the last corrected 
values for the spot weights as input. MC simulates random 
errors by shifting randomly the starting point of each 
particle, according to the distribution of random errors. Such 
strategy assumes a sufficient number of treatment fractions. 
The method was applied to lung and prostate cases. For both 
patients the range error was set to 3%, systematic setup error 
to 5mm and standard deviation for random errors to 5 mm. 
Comparison between full robust optimization and the mixed 
strategy (with 3 updates of C) is presented. 
 
Results: Target coverage was far below the clinical 
constraints (D95 > 95% of the prescribed dose) for plans 
where random errors were not simulated, especially for lung 
case. However, by using full robust or mixed optimization 
strategies, the plans achieved good target coverage (above 
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clinical constraints) and overdose comparable to the nominal 
case. Doses to organs at risk were similar for the three plans 
in both patients. 
 
 
Conclusion: The proposed strategies achieved robust plans in 
term of target coverage without increasing the dose to the 
CTV nor to the organs at risk. Full robust optimization gives 
better results than the mixed strategy, but the latter can be 
useful in cases where a MC engine is not available or too 
computationally intensive for beamlets calculation.  
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Purpose or Objective: The aim of the study was to develop a 
fully automated treatment planning procedure to generate 
VMAT plans for stage III/IV non-small cell lung cancer (NSCLC) 
patients, treated with curative intent, and to compare them 
with manually generated plans. 
 
Material and Methods: Based on treatment plans of 7 
previously treated patients, the clinical protocol, and 
physician’s treatment goals and priorities, our in-house 
developed system for fully automated, multi-criterial plan 
generation was configured to generate VMAT plans for 
advanced stage NSCLC patients without human interaction. 
For 41 independent patients, treated between January and 
August 2015, automatic plan generation was then compared 
with manual plan generation, as performed in clinical 
routine. Differences in PTV coverage, dose conformality R50 
(the ratio between the total volume receiving at least 50% of 
the prescribed dose and the PTV volume) and sparing of 
organs at risk were quantified, and their statistical 
significance was assessed using a Wilcoxon test. 
 
Results: For 35 out of 41 patients (85%), the automatically 
generated VMAT plans were clinically acceptable as judged 
by two physicians. Compared to the manually generated 
plans, they considered the quality of automatically generated 
plans superior for at least 67% of patients, due to a 
combination of better PTV coverage, dose conformality and 
sparing of lungs, heart and oesophagus (positive values in 
figure). For the other acceptable plans plan quality was 
considered equivalent. On average, PTV coverage (V95) was 
improved by 1.1 % (p<0.001), the near-minimum dose in the 
PTV (D99) by 0.55 Gy (p=0.006) and the R50 by 12.4% 
(p<0.001). The mean lung dose was reduced by 0.86 Gy 
(4.6%, p<0.001), and the V20 of the lungs by 1.3 % (p=0.001). 
For some patients it was possible to improve PTV V95 by 
3.8%, D99 by 3.3 Gy, to reduce mean lung dose by 3.0 Gy and 
V20 by 6.2%. All plans fulfilled the planning constraints for 
the spinal cord, heart and plexus. 
For the 6 automated VMAT plans that were initially not 
acceptable, it took a dosimetrist less than 10 minutes hands-
on time to manually fine-tune the VMAT plan in our TPS to 
make it acceptable. In contrast, to generate a VMAT plan 
from scratch 3-4 hours were required.  
For 5 out of 10 patients with a PTV prescription dose of less 
than 66 Gy in the manual plan, we were able to escalate the 
tumour dose using automated planning. For two patients dose 
escalation from 60 Gy to 66 Gy was possible, for other 
patients from 60.5 Gy to 66 Gy, 45 Gy to 57.75 Gy, and 55 Gy 




Conclusion: Using our fully automated treatment planning 
procedure, clinically deliverable, high quality VMAT plans for 
advanced stage NSCLC patients may be generated without 
human interaction for the far majority of patients. When 
manual adjustments were required, they took very little 
hands-on time only. With automated planning, a higher 
tumour dose could be achieved for a subgroup of patients. 
Clinical introduction has been started. 
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Purpose or Objective: In stereotactic body radiation 
therapy, high accuracy is required to deliver high fraction 
doses with steep dose gradients. Non-coplanar beam setups 
may improve plan quality. This can be realized with a robotic 
CyberKnife (CK, Accuray Inc, Sunnyvale, USA). Due to its 
tumor tracking features, CTV-PTV margins may be reduced 
compared to linac treatment. In previous works we have built 
and validated a system for fully automated, multi-criterial 
VMAT plan generation (iCycle/Monaco). Recently, we have 
extended the system with an option for fully automated plan 
generation for the CK (iCycle/Multiplan). In this study we 
have used fully automated plan generation for un-biased 
comparison of non-coplanar CK with coplanar VMAT at a 
linac, for prostate SBRT. 
 
Material and Methods: Our in-house iCycle system was first 
coupled to the Multiplan TPS that comes with the CK 
treatment unit. The iCycle/Multiplan and iCyle/Monaco 
systems were then configured for automated prostate SBRT 
plan generation for CK and linac-VMAT, respectively. Plans 
were then generated for 10 prostate SBRT patients, 
delivering 38 Gy in 4 fractions. Three clinically deliverable 
